Zealand Pharma reported strong progress in 2026 with positive Phase 2 results for petrelintide, initiating Phase 3 trials for obesity treatment, and Boehringer Ingelheim's survodutide showing significant weight loss and cardiovascular safety in Phase 3 trials. The company also received a positive CHMP opinion for Zeydovio in short bowel syndrome and expanded research capabilities through a new hub in Cambridge and a collaboration with Generate Biomedicines using AI for protein therapeutics. Financially, Zealand Pharma maintained solid revenue and profit, narrowed its operating expense guidance, and plans further clinical and regulatory milestones in 2026 and beyond.
Zealand Pharma's recent financial results provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 12, 2026 12:51 WIB: out of 150 health-sector US stocks, 88 rose and 59 fell. Among notable movers, RVMD traded at USD 180.86 with a 6.32% decline and a typical hold time of 13 days, ABEO dropped 6.31% to USD 2.30 with a 62% sell order activity and a 22-day hold, while TNGX gained 6.30% to USD 25.83 with balanced order activity and a shorter 4-day hold time.
Space42 reported an 11% increase in revenues to USD 404 million and a 30% rise in normalized EBITDA to USD 194 million for the first nine months of 2026. Growth was driven by strong performances in both Space Services, boosted by a major government c...
YYForce Inc. forecasts revenue of $70 million for fiscal year 2026, marking a 22% increase from $57.2 million in 2025. This growth is attributed to rising demand for its AI-driven Workforce OS platform, expanded robotics deployments, and increased re...
YYForce Inc. has issued a revenue guidance of $70 million for the fiscal year ending December 31, 2026, representing an approximate 22% increase from the audited $57.2 million revenue in fiscal 2025. This growth is attributed to rising demand for its...
YYForce Inc. forecasts its fiscal 2026 revenue to reach $70 million, a 22% increase from the audited $57.2 million in fiscal 2025. This growth is attributed to rising demand for its AI-based workforce management platform, increased adoption of commer...
YYForce Inc. forecasts revenue of $70 million for fiscal year 2026, marking a 22% increase from $57.2 million in 2025. This growth is fueled by rising demand for its AI-powered Workforce OS platform, commercial robotics, and recurring software and se...
